|
Bud & Mary's Advances Cannabis Research to Improve Therapeutic Applications and Bridge Gaps in Wellness Efficacy
Friday, February 21, 2025
Scientific studies on neurodegenerative diseases, sleep, and consumer products aim to set new standards for safety, accuracy, and medical potential
DENVER, Feb. 13, 2025 /PRNewswire-PRWeb/ -- MedPharm DBA Bud & Mary's, a federally licensed cannabis research and pharmaceutical development company, continues to lead scientific advancements in cannabis-based therapeutics as the only U.S. company with a DEA Schedule I licensed research facility. With several active studies addressing neurodegenerative diseases such as Alzheimer's, sleep health and product consistency, the company remains at the forefront of industry innovation.
"Our research tackles key challenges in cannabis science, from investigating how cannabinoid-based therapies can treat neurodegenerative diseases to exploring potential benefits for sleep quality and anxiety," said Dr. Duncan Mackie, Director of Pharmacology & Experimental Therapeutics at Bud & Mary's. "By applying rigorous scientific methods and working with leading academic institutions, we are building the data necessary to inform regulatory decisions, guide industry standards, and develop the future of cannabis-based therapeutics."
Bud & Mary's latest research initiatives include:
-- Cannabinoids for Alzheimer's Disease: Bud & Mary's research focuses on
isolating unique cannabinoids to explore their role in reducing
neuroinflammation associated with Alzheimer's disease. Early findings
may help regulate the immune system in the brain, potentially reducing
neural damage associated with Alzheimer's. This study is laying the
groundwork for future cannabinoid-based drug development for
neurodegenerative disorders.
-- Sleep Clinical Trial with the University of Iowa: A pilot study is
underway to assess the effects of a patented, intradermal
cannabinoid-based gel on sleep disturbances among adults over 50.
Initial data suggests that participants using the gel report improved
sleep duration and quality, as well as reductions in nighttime
awakenings. The study continues to track long-term effects on sleep and
pain management.
-- LABeL Research Project: Cannabis Product Label Accuracy: In partnership
with the University of Colorado Boulder, Bud & Mary's has independently
tested more than 300 retail cannabis products to compare labeled potency
claims against actual cannabinoid content. The study identified
discrepancies in potency accuracy across different product types, with
bulk flower showing the largest variations. Findings suggest systematic
inconsistencies between state-licensed testing labs, highlighting the
need for standardized testing requirements. The first phase of this
study is pending publication in a peer-reviewed journal, with
recommendations for regulatory improvements.
This research has produced active patents for Bud & Mary's including Water-Based Extraction and Purification Processes for Cannabinoid Acids; Hybrid Extraction Process for Cannabinoids and Related Methods; Brain Health Formulation; Pharmaceutical Packaging Device; Self-Emulsifying Anhydrous Intradermal Depot Gel; Water Soluble, Powdered Cannabinoid and/or Terpene Extract.
With a DEA Schedule I licensed research facility, an ISO17025-accredited analytical laboratory, and a cGMP and GACP-certified production site, Bud & Mary's is at the forefront of cannabis research. Its efforts include partnerships with Colorado State University Pueblo's Institute of Cannabis Research; University of Colorado's CU-Change; CU Anschutz's Colorado School of Public Health; Northwestern University Feinberg School of Medicine's Department of Physical Medicine & Rehabilitation; Edward Hines Jr. VA Research Service & the Center of Innovation for Complex Chronic Health Care; University of Illinois Chicago Center for Dissemination and Implementation Science; Colorado State University's Department of Psychology; University of Iowa College of Public Health's Cannabis and Older Person Study (COPS) and the Institute for Clinical and Translational Science.
Supporting a broader conversation on evidence-based cannabis research and regulation, Dr. Mackie will speak at UC Anschutz in the Skaggs School of Pharmacy and Pharmaceutical Sciences' Innovation and Entrepreneurship Monthly Seminar Series during the Faculty Forum on Friday, Feb. 21, at 1:30pm. Bud & Mary's will also participate in the First Annual Dinner for the Advancement of Cannabis Science on Tuesday, February 25, supporting a broader conversation on evidence-based cannabis research and regulation. The company's support aligns with its commitment to fostering collaboration between researchers, policymakers, and industry leaders.
For more information on Bud & Mary's research initiatives or to schedule an interview, contact Shawna Seldon McGregor at 917-971-7852 or shawna@themaverickpr.com.
Bud & Mary's: Crafted for You, Powered by Science.
At Bud & Mary's, we take a science-driven approach to crafting premium cannabis products designed for every individual. From our best-selling BATCH vape cartridges and CURATED flower to our innovative water-soluble TheMyx powder and wellness-focused brands Become and NUO, every product is developed with care, precision, and an unwavering commitment to quality. Locally grown and rigorously tested, Bud & Mary's products meet the highest standards of safety, consistency, and excellence. Through it all, we've remained true to our roots--family-driven, people-focused, and dedicated to pushing the boundaries of cannabis innovation. For more information, visit BudMary.com. Continue the conversation on Facebook, Instagram, X, LinkedIn and TikTok.
Media Contact
Shawna Seldon McGregor, Bud & Mary's, 917-971-7852, shawna@themaverickpr.com, https://www.budmary.com/
View original content to download multimedia:https://www.prweb.com/releases/bud--marys-advances-cannabis-research-to-improve-therapeutic-applications-and-bridge-gaps-in-wellness-efficacy-302375698.html
SOURCE Bud & Mary's
|
|
|
|
|
|
 |
VIAVI Highlights Test Solutions for AI Infrastructure Development, Manufacturing and Deployment at OFC 2025 | Mar 28, 2025
|
|
Oracle Helps Customers Boost Employee Engagement with Strategic Communications and Internal Events | Mar 28, 2025
|
|
ThreatQuotient positioned as a Leader in the SPARK Matrix(TM): Digital Threat Intelligence Management, 2025 by QKS Group | Mar 28, 2025
|
|
Orium Launches Composable Accelerator for Shopify | Mar 28, 2025
|
|
Madame Rachida Dati, French Minister of Culture, has granted official recognition to thierry Ehrmann's Abode of Chaos as a 'total work of art', the global headquarters of Artprice by Artmarket. | Mar 28, 2025
|
|
Datacenter Dynamics Makes History with LoneStar - Becoming the World's First Magazine to Reach the Moon | Mar 28, 2025
|
|
Nosto reports 323% growth of Personalized Search after 2024 Gartner MQ inclusion | Mar 28, 2025
|
|
Western Union forms strategic partnership with HCLTech to transition to an AI led platform operating model | Mar 28, 2025
|
|
Wealthbox Expands to Canada with In-Country Data Hosting | Mar 28, 2025
|
|
Direct Digital Holdings Launches "Practical Generative AI Use Cases & Tools for DMOs" to Help Break New Ground in Destination Marketing With AI | Mar 28, 2025
|
|
|
|
